| Eugenia Curette, | |
|
116 Bertrand Dr, Lafayette, LA 70506-5632 | |
| (337) 261-8781 | |
| Not Available |
| Full Name | Eugenia Curette |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 116 Bertrand Dr, Lafayette, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023534070 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (Louisiana) | Secondary |
| 171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Eugenia Curette, 116 Bertrand Dr, Lafayette, LA 70506-5632 Ph: () - | Eugenia Curette, 116 Bertrand Dr, Lafayette, LA 70506-5632 Ph: (337) 261-8781 |
News Archive
With a concern that the automatic reporting of estimated glomerular filtration rate (the flow rate of filtered fluid through the kidney, which is used to define the stage and severity of chronic kidney disease) may result in unnecessary referrals by physicians, new research indicates that automated laboratory reporting was associated with a significant increase in first-time visits to a kidney specialist, particularly among those at increased risk of late detection of kidney disease (such as older or female patients), according to a study in the March 24/31 issue of JAMA.
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that its product candidate CRTX-067 is an ANDA filing for a generic 10 mg chlorpheniramine polistirex/8 mg hydrocodone polistirex suspension product that will be a generic substitute for the product currently sold under the Tussionex brand name by UCB, Inc.
Get ready for the hottest topics in oral health with the EuroPerio Series, a virtual initiative of the European Federation of Periodontology.
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge, and the AstraZeneca IMED Biotech Unit reveals new insights into how the PTEN gene may control cell growth and behavior and how its loss contributes to the development and advancement of certain cancers.
Fitch Ratings assigns a 'BB+' rating to the following Indiana Health Facilities Financing Authority revenue bonds issued on behalf of Methodist Hospitals (Methodist):
› Verified 9 days ago